OOIR: Observatory of International Research

Papers

(The H4-Index of JNCI-Journal of the National Cancer Institute is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Correction to: ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications	207
Vertical integration in oncology: what does it mean for patients with cancer?	177
Re: Deng and Heybati	132
Response to Liu and Zhang	130
Factors associated with timely COVID-19 vaccination in a population-based cohort of patients with cancer	103
The National Cancer Institute Funding of Global Research: Lessons Learned and Opportunities Going Forward	96
Evaluating a blood test for colon cancer screening: how simulation modeling can inform clinical policy making and research	85
Addressing Diversity, Equity, and Inclusion at the JNCI Journals	84
Pre- and post-diagnostic use of antihypertensive medications and stage I-III colorectal cancer survival: prospective cohort study	77
Reduced adipose tissue with limited loss of lean mass after weight loss: results from the Prostate Cancer Active Lifestyle Study	72
Independent associations between obesity, glucose metabolism, and breast cancer risk through unrelated pathways	71
Mediators of Racial Disparities in Heart Dose Among Whole Breast Radiotherapy Patients	68
Discovering plasma proteins associated with breast cancer incidence in postmenopausal women in the Atherosclerosis Risk in Communities study	68
RE: Exploring the cross-cancer effect of circulating proteins and discovering potential intervention targets for 13 site-specific cancers	66
Incorporation of patient-reported outcomes in pediatric cancer clinical trials: design, implementation, and dissemination	64
Increasing diversity in clinical trials: demographic trends at the National Cancer Institute, 2005-2020	62
The National Cancer Policy Forum: a strong voice for improving cancer care and outcomes	61
Rare cancers research: Current state of knowledge and emerging opportunities for prevention and interception	60
Joint associations of accelerometer-measured physical activity and cardiovascular-kidney-metabolic syndrome stages with the risks of cancer and all-cause mortality	59
The impact of HIV on cervical cancer elimination in KwaZulu-Natal: a comparative modeling analysis	59
Dyslipidemia and cardiovascular disease among childhood cancer survivors: a St. Jude Lifetime Cohort report	58
RE: Use of artificial intelligence for cancer clinical trial enrollment	57
Cancer prevention in context: interplay of perceived discrimination, neighborhood deprivation, and cancer-related risk and protective factors	52
Ethylene oxide emissions and incident breast cancer and non-Hodgkin lymphoma in a US cohort	51
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial	50

Method of primary breast cancer detection and the disease-free interval, adjusting for lead time	50
Long-term aspirin use and cancer risk: a 20-year cohort study	48
Understanding risk factors for endometrial cancer in young women	47
Metabolically (un)healthy obesity and risk of obesity-related cancers: a pooled study	47
Survivorship after adolescent and young adult cancer: models of care, disparities, and opportunities	47
RE: Prevalence of cancer survivors in the United States	46
The National Cancer Institute clinical trials planning meeting to address gaps in observational and intervention trials for cancer-related cognitive impairment	46
Systematic investigation of genetically determined plasma and urinary metabolites to discover potential interventional targets for colorectal cancer	46
Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line col	45
Impact of knowledge of human papillomavirus positivity on cervical cytology performance in Latin America	45
Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study	45
RE: Autoimmune disease and the risk of anal cancer in the US elderly population	45
Association Between Medicaid Expansion Under the Affordable Care Act and Survival Among Newly Diagnosed Cancer Patients	45
Health-related quality of life by race, ethnicity, and country of origin among cancer survivors	45
Leisure-time physical activity after diagnosis and survival by cancer type: a pooled analysis	44
Response of bilateral Wilms tumor to chemotherapy suggests histologic subtype and guides treatment	41
Epidemiology of early vs late recurrence among women with early stage estrogen receptor–positive breast cancer in the Pathways Study	41
Urgent need to mitigate disparities in federal funding for cancer research	41